A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir

Abstract EN

The treatment of primary nephrotic syndrome such as minimal change nephropathy, membranous nephropathy, and focal segmental glomerulosclerosis nephropathy remains challenging.

Whilst most cases of idiopathic nephrotic syndrome respond to steroid therapy and experience a limited number of relapses prior to complete remission, some cases suffer from frequent relapses and become steroid dependent or are primarily steroid resistant.

Treatment options are limited to immunosuppressive drugs with significant side effect profiles.

New modalities targeting novel pathways in the pathogenesis of nephrotic syndrome are actively sought.

Here we report the case of a patient with steroid dependent focal segmental glomerulosclerosis (FSGS) nephrotic syndrome with a favourable response to a novel proteasome inhibitor saquinavir.